Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma

Key Points

• Targeted therapies show promise in improving outcomes for RET fusion-positive papillary thyroid carcinoma.
• Recent clinical trials demonstrate efficacy and safety of novel treatments, with over 60% response rates reported.
• Observational analysis across diverse populations reveals insights into molecular pathogenesis, influencing therapeutic strategies.
• These findings may enable personalized treatment approaches for patients with RET fusion-positive tumors.